Please login to the form below

Not currently logged in
Email:
Password:

Synergy Vision wins gold Investors in People accreditation

Agency upgraded from silver to gold status

SV

London, UK-based medical communications agency Synergy Vision has been granted gold accreditation status from Investors in People (IIP).

IIP said the agency “works effectively together to deliver the difference to its clients that will positively affect patient care”.

Synergy was first awarded Core IIP accreditation back in 2011, which was upgraded to silver in 2013 and now the group has acquired gold status. The progression in IIP status reflects on how a company’s career development, and reward and recognition programmes have developed over the years.

Ffyona Dawber, Synergy Vision’s managing director, said: “We realise that our team is Synergy Vision’s greatest asset.

“It’s so important to invest in making sure everyone - through all levels of the company - enjoys their work and can progress into new roles whenever they are ready.

“We are happy to see that the IIP assessment has recognised the efforts we put into making our team happy.”

Last year the agency was the highest placed medical communications agency in the UK’s Best Workplaces: Small Category awards.

Article by
Gemma Jones

12th May 2017

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Where is health behaviour change heading?
Cures rely on patient adherence to succeed, and health behaviour change in any non-compliant patient is essential, this post explores where health behaviour change is heading....
Pharma email marketing: Your top 12 tips
Used correctly, email can be one of the most effective and cost-efficient channels for a pharma company to use. To help you get the most from it, we've rounded up...
arrow
Patently unclear?
The challenge of protecting biotech innovations...

Infographics